JPMorgan Chase & Co’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $39M | Sell |
1,198,770
-701,409
| -37% | -$22.8M | ﹤0.01% | 1339 |
|
|
2025
Q1 | $71.8M | Buy |
1,900,179
+164,516
| +9% | +$6.21M | 0.01% | 995 |
|
|
2024
Q4 | $142M | Buy |
1,735,663
+307,903
| +22% | +$25.2M | 0.01% | 726 |
|
|
2024
Q3 | $163M | Buy |
1,427,760
+215,317
| +18% | +$24.6M | 0.01% | 718 |
|
|
2024
Q2 | $91.6M | Buy |
1,212,443
+50,666
| +4% | +$3.83M | 0.01% | 873 |
|
|
2024
Q1 | $79.4M | Buy |
1,161,777
+756,443
| +187% | +$51.7M | 0.01% | 970 |
|
|
2023
Q4 | $25.5M | Sell |
405,334
-232,387
| -36% | -$14.6M | ﹤0.01% | 1468 |
|
|
2023
Q3 | $32.5M | Buy |
637,721
+281,312
| +79% | +$14.3M | ﹤0.01% | 1221 |
|
|
2023
Q2 | $17.8M | Buy |
356,409
+63,513
| +22% | +$3.17M | ﹤0.01% | 1623 |
|
|
2023
Q1 | $11M | Buy |
292,896
+39,964
| +16% | +$1.5M | ﹤0.01% | 1923 |
|
|
2022
Q4 | $12.1M | Buy |
252,932
+72,805
| +40% | +$3.49M | ﹤0.01% | 1771 |
|
|
2022
Q3 | $4.32M | Buy |
180,127
+135,955
| +308% | +$3.26M | ﹤0.01% | 2432 |
|
|
2022
Q2 | $961K | Buy |
44,172
+17,380
| +65% | +$378K | ﹤0.01% | 3502 |
|
|
2022
Q1 | $647K | Buy |
26,792
+6,390
| +31% | +$154K | ﹤0.01% | 3858 |
|
|
2021
Q4 | $486K | Sell |
20,402
-5,655
| -22% | -$135K | ﹤0.01% | 4094 |
|
|
2021
Q3 | $661K | Buy |
26,057
+4,176
| +19% | +$106K | ﹤0.01% | 3823 |
|
|
2021
Q2 | $493K | Sell |
21,881
-43,064
| -66% | -$970K | ﹤0.01% | 4005 |
|
|
2021
Q1 | $1.28M | Buy |
64,945
+27,454
| +73% | +$542K | ﹤0.01% | 3499 |
|
|
2020
Q4 | $996K | Buy |
37,491
+30,703
| +452% | +$816K | ﹤0.01% | 3386 |
|
|
2020
Q3 | $350K | Buy |
+6,788
| New | +$350K | ﹤0.01% | 3524 |
|